E Bora1, B B Akdede2, K Alptekin2. 1. Department of Psychiatry,Melbourne Neuropsychiatry Centre,University of Melbourne and Melbourne Health,Carlton South,Victoria,Australia. 2. Department of Psychiatry,Dokuz Eylul University School of Medicine,Izmir,Turkey.
Abstract
BACKGROUND: Individuals with schizophrenia are at greater risk for metabolic syndrome (MetS) which is associated with cognitive deficits in the general population. MetS might be potentially an important contributing factor to cognitive impairment in schizophrenia. METHOD: In the current systematic review and meta-analysis, the findings of 18 studies investigating the association between MetS (and its components) with cognitive impairment in schizophrenia are reviewed. RESULTS: Co-morbidity of MetS (d = 0.28) and diabetes mellitus (d = 0.28) were both associated with more severe cognitive deficits in schizophrenia. There was also evidence for a significant relationship between cognitive impairment in schizophrenia and each of the components of MetS including hypertension, dyslipidemia, abdominal obesity and diabetes. CONCLUSIONS: MetS is significantly associated with cognitive impairment in schizophrenia and can potentially contribute to functional decline observed in some patients with schizophrenia throughout the course of illness.
BACKGROUND: Individuals with schizophrenia are at greater risk for metabolic syndrome (MetS) which is associated with cognitive deficits in the general population. MetS might be potentially an important contributing factor to cognitive impairment in schizophrenia. METHOD: In the current systematic review and meta-analysis, the findings of 18 studies investigating the association between MetS (and its components) with cognitive impairment in schizophrenia are reviewed. RESULTS: Co-morbidity of MetS (d = 0.28) and diabetes mellitus (d = 0.28) were both associated with more severe cognitive deficits in schizophrenia. There was also evidence for a significant relationship between cognitive impairment in schizophrenia and each of the components of MetS including hypertension, dyslipidemia, abdominal obesity and diabetes. CONCLUSIONS: MetS is significantly associated with cognitive impairment in schizophrenia and can potentially contribute to functional decline observed in some patients with schizophrenia throughout the course of illness.
Authors: Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin Journal: Int J Mol Sci Date: 2022-01-22 Impact factor: 5.923
Authors: H K Luckhoff; S Kilian; M R Olivier; L Phahladira; F Scheffler; S du Plessis; B Chiliza; L Asmal; R Emsley Journal: Metab Brain Dis Date: 2019-01-02 Impact factor: 3.584
Authors: Garcia Ashdown-Franks; Joseph Firth; Rebekah Carney; Andre F Carvalho; Mats Hallgren; Ai Koyanagi; Simon Rosenbaum; Felipe B Schuch; Lee Smith; Marco Solmi; Davy Vancampfort; Brendon Stubbs Journal: Sports Med Date: 2020-01 Impact factor: 11.136
Authors: Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg Journal: Behav Brain Res Date: 2021-01-14 Impact factor: 3.332